News about Drug Discovery & Development

Eisai Signs Deal to Develop Tasurgratinib in Greater China Region with SciClone

Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched.

Drug Discovery & Development | 01/03/2025 | By Aishwarya |  420

BridGene Biosciences Signs Deal with Takeda to Discover Small Molecule Drugs

Under the terms of the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against challenging targets in immunology and neurology.

Drug Discovery & Development | 26/02/2025 | By Aishwarya |  482

Tiziana Life Sciences Signs Deal for Product Development Services with Renaissance Lakewood

Under this agreement, Renaissance will use its extensive expertise in pharmaceutical-nasal product development and manufacturing to support the production of intranasal foralumab, ensuring compliance with the highest quality and regulatory requirements.

Drug Discovery & Development | 24/02/2025 | By Aishwarya |  220

Biogen and Stoke Therapeutics to Develop and Commercialize Zorevunersen

Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome.

Drug Discovery & Development | 20/02/2025 | By Aishwarya |  395

Innocan Pharma Secures its First Patent in India for its Liposomal CBD Injection

This granted patent protects Innocan's synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), designed for precise dosing and sustained release of Synthetic CBD into the bloodstream.

Drug Discovery & Development | 19/02/2025 | By Aishwarya |  513

Glenmark Pharmaceuticals Inc., USA Launches Clindamycin Phosphate Foam, 1 percent

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1 percent.

Drug Discovery & Development | 12/02/2025 | By Manvi |  273

Hoth Therapeutics Collaborates with OnTargetx R&D Inc. to Advance Research for its Cancer-Fighting Therapeutic 'HT-KIT'

This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT.

Drug Discovery & Development | 11/02/2025 | By Manvi |  402

Cosmo and Glenmark Receive UK MHRA Approval of Winlevi for Treatment of Acne

Winlevi® is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions.

Drug Discovery & Development | 10/02/2025 | By Aishwarya |  598

Jupiter Neurosciences Signs JOTROL Manufacturing Agreement with Catalent

Under the terms of the agreement, Catalent will manufacture clinical batches of JOTROL, Jupiter’s proprietary resveratrol-based therapeutic, using an optimized softgel formulation.

Drug Discovery & Development | 04/02/2025 | By Aishwarya |  404

Akums Combines Two Potent Diabetes Medicines for Enhanced Treatment Efficacy

Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, aids in eliminating excess glucose via urine while delivering additional benefits such as improved cardiovascular and renal outcomes, along with better weight management.

Drug Discovery & Development | 03/02/2025 | By Aishwarya |  699